Flagship Pioneering, the venture firm behind Moderna and other biotechs, has been awarded a $47 million contract from the U.S. Department of Defense to develop medical countermeasure technologies. The award was confirmed by two outlets: Fierce Biotech describes the funding as coming from the Department of War, while STAT identifies the payer as the Department of Defense, calling it a Pentagon contract.
Both sources agree on the core purpose: advancing technologies that can respond to biological threats. Fierce Biotech frames the work as targeting "emerging threats," while STAT specifies "biological threats" more generally. The slight difference in wording does not change the thrust of the program, which is to bolster preparedness against pathogens or other biological agents that could harm military personnel or civilians.
The contract fits a broader pattern of the Pentagon investing in biotech startups to accelerate medical readiness. Flagship's platform companies, which often spin out novel therapeutic or diagnostic approaches, are positioned to contribute rapid-response tools, though the specific technologies and timelines were not disclosed in either report.